Sirolimus Rx how to inject: a step-by-step protocol

Last updated 2026-07-27

Is sirolimus even given by injection?

No, not in any standard sense. Sirolimus (brand name Rapamune, chemically identical to rapamycin) is FDA-approved as an oral tablet and oral solution for preventing organ transplant rejection ^[1]. The two FDA-approved sirolimus-related injectable-adjacent products are Fyarro, an albumin-bound IV formulation of a different sirolimus derivative used for a rare soft tissue cancer called malignant perivascular epithelioid cell tumor (PEComa) ^[2], and Hyftor, a topical gel for tuberous sclerosis skin lesions ^[3]. Neither is an at-home injection product, and neither is used for longevity. If you're searching "how to inject sirolimus" because you've seen peptide communities discuss subcutaneous protocols for things like BPC-157 or growth hormone secretagogues and assumed rapamycin works the same way, it doesn't. Rapamycin is a macrocyclic lactone, poorly water-soluble, and formulated for oral absorption with specific excipients (Rapamune tablets and oral solution use a formulation designed around gut absorption, not tissue injection) ^[1]. There's no compounded injectable sirolimus product with real stability or dosing data behind it that a longevity user would responsibly self-administer. The honest answer to "how to inject sirolimus" is: you don't, for this purpose. What people actually mean when they ask this is usually one of two things: they want the correct oral dosing protocol, or they've confused sirolimus with a peptide. This article covers the oral protocol in the depth an injection guide would have covered a syringe protocol, because that's the actual off-label practice being used by longevity self-experimenters and some direct-care physicians.

So what does the actual off-label sirolimus protocol look like?

Almost universally, it's a weekly oral dose, not a daily one, and not an injection. The most cited off-label protocol, associated with Dr. Alan Green's clinical experience and referenced across longevity physician networks, uses roughly 5 to 6 mg once per week, adjusted by body weight and blood levels, rather than the low daily doses (roughly 1 to 2 mg per day) used in transplant medicine ^[1]. The logic behind weekly dosing comes partly from animal studies where intermittent dosing achieved lifespan extension with less immune suppression than continuous dosing, and partly from sirolimus's long half-life, which allows a once-weekly schedule to still maintain a therapeutic pulse ^[1]. For a full breakdown of how that dose scales by weight and blood level target, see Sirolimus Rx dosage and the Sirolimus Rx dosage calculator. There is no FDA-approved dose for longevity, aging, or lifespan extension in humans, full stop. Every number circulating in longevity forums, including the 5 to 6 mg weekly figure, is extrapolated from transplant pharmacology and animal data, not from a completed human aging trial. Nobody has good data confirming an optimal weekly human longevity dose because that trial hasn't been run.

What is the human evidence for sirolimus and lifespan, really?

The animal evidence is genuinely strong. The human evidence, for lifespan specifically, does not exist yet. That gap is the entire story, and it's worth being blunt about it every time this topic comes up. The anchor data point is the National Institute on Aging's Interventions Testing Program (ITP), which tested rapamycin in genetically heterogeneous mice across three labs. The ITP found rapamycin extended median lifespan in mice by roughly 9 to 26% depending on dose, sex, and start age, with effects seen even when treatment began late in life (starting at 600 days of age, roughly equivalent to a 60-year-old human) ^[4]. A 2016 paper from the same program reported that even a 3-month exposure period initiated at 20 months of age was enough to produce lifespan extension in mice ^[5]. What doesn't exist: any completed randomized controlled trial measuring human lifespan or all-cause mortality with rapamycin in healthy adults. The closest human data come from small studies on surrogate markers, not survival. A 2018 study by Mannick and colleagues, published in Science Translational Medicine, found that RTB101 (a different but related TOR inhibitor) reduced the incidence of respiratory tract infections in elderly volunteers, functioning as indirect evidence that TOR pathway inhibition affects human immune aging, but this measured infection rates, not lifespan . There's also earlier work from the same research group showing low-dose mTOR inhibitor combinations improved influenza vaccine antibody response in adults over 65 . These are interesting immune-function signals in humans. They are not lifespan data. Anyone telling you sirolimus is "proven" to extend human life is overstating the evidence. Anyone telling you the mouse data is meaningless is understating it. The honest position: strong, repeated, multi-lab animal evidence, and zero completed human lifespan trials.

What are the real risks people should know before starting?

Three categories matter most for the off-label intermittent protocols people are actually using: immunosuppression, mouth ulcers, and metabolic effects. Immunosuppression is the core, FDA-labeled effect of the drug, since that's exactly why it's approved for transplant patients. The prescribing information for Rapamune carries a boxed warning about increased susceptibility to infection and the risk of malignancies (particularly skin cancer and lymphoma) associated with the degree of immunosuppression, based on transplant-population data where doses and durations are far higher than longevity protocols ^[1]. Whether a weekly, lower-dose longevity protocol carries meaningfully lower immune risk than continuous transplant dosing is a reasonable hypothesis, supported by some animal data, but it hasn't been confirmed in a long-term human safety trial. Mouth ulcers (stomatitis) are one of the most commonly reported side effects in the Rapamune label, and they show up frequently in longevity user reports too, especially in the days right after a weekly dose ^[1]. They're usually manageable, but they're common enough that anyone starting the drug should expect the possibility, not be surprised by it. Metabolic effects are the other big one. Sirolimus is associated with elevated LDL cholesterol and triglycerides, and with new-onset hyperglycemia in some patients, effects documented in the transplant literature and monitored via routine labs in that population ^[1]. Longevity users on intermittent low-dose protocols report this less often than continuous transplant-dose patients, but it isn't zero risk, and it's a reason lipid panels and fasting glucose belong in any monitoring plan. Other documented effects include delayed wound healing, elevated risk of certain infections, and interaction with a long list of drugs metabolized through CYP3A4, which is why blood level monitoring and a doctor who knows the drug matter more here than with most longevity supplements ^[1].

How is sirolimus actually taken (since it isn't injected)?

Oral, on an empty or consistently fed stomach (consistency matters more than empty vs. fed, per the FDA label, since food changes absorption and you want that variable held constant week to week) ^[1]. The tablet or oral solution is swallowed, not injected, and not applied topically outside the narrow Hyftor indication for tuberous sclerosis skin lesions ^[3]. For the oral solution specifically, the FDA label instructs mixing the dose in at least 2 ounces (60 mL) of water or orange juice right before drinking, using a provided dosing syringe for accurate measurement, and not using grapefruit juice, since grapefruit inhibits the CYP3A4 enzyme that metabolizes the drug and can push blood levels dangerously high ^[1]. Because weekly off-label dosing is a large single dose relative to daily transplant dosing, some users split it, taking it as one dose rather than dividing across the day, though practice varies by prescriber. There's no compounded injectable version with real pharmacokinetic data behind it, so any "injection protocol" circulating outside a hospital or research IV-infusion context (like Fyarro, which is only for its cancer indication) isn't something responsibly documented for longevity self-use ^[2]. If you're looking at questions like reconstitution or injection sites because you've seen those terms used for other longevity peptides and assumed the same steps applied here, they don't transfer. See how to reconstitute Sirolimus Rx and Sirolimus Rx injection sites for how those concepts are actually handled for products where they apply, and why sirolimus itself is the oral exception.

Why do people confuse sirolimus with an injectable peptide?

Mostly because of where the conversation happens. Sirolimus longevity dosing gets discussed in the same online communities, forums, and telehealth platforms as injectable peptides like BPC-157, ipamorelin, or NAD+, and the shared context blurs the administration method in people's minds. There's also a partial technical reason: some longevity-focused compounding pharmacies do prepare injectable versions of other molecules (peptides are typically lyophilized powders reconstituted with bacteriostatic water and injected subcutaneously), and someone moving from a peptide protocol to sirolimus may assume the same preparation steps apply. They don't. Sirolimus ships as an oral tablet or oral solution from a licensed pharmacy with a prescription, the same dispensing model as any other oral prescription drug, not a vial-and-syringe kit. A rapamycin-specific compounded topical cream also exists and gets discussed for skin aging and rosacea-adjacent uses, sometimes compared loosely to Hyftor's approved topical formulation for tuberous sclerosis, which adds another non-injection route to the confusion ^[3]. None of this changes the core fact: for the longevity protocol most people are asking about, the route is oral.

How does sirolimus compare to rapamycin, is there a difference in how you'd take it?

No difference. Sirolimus is the generic drug name; rapamycin is the original name given to the compound isolated from Streptomyces hygroscopicus, a bacterium found in soil samples from Easter Island (Rapa Nui), which is also where the name comes from ^[1]. They are the same molecule, and "rapamycin" and "sirolimus" are used interchangeably in the literature and in longevity communities. What does vary is the brand and formulation: Rapamune (the FDA-approved oral tablet/solution for transplant), generic sirolimus tablets, and compounded sirolimus preparations from compounding pharmacies serving longevity-focused prescribers all contain the same active molecule, but dosing strength, filler ingredients, and consistency of absorption can differ between a generic tablet and a compounded capsule. That's part of why blood level monitoring (a trough sirolimus level, drawn by standard lab blood draw, not related to injection) matters regardless of which formulation you're on. Everolimus is a related but distinct rapalog (a rapamycin analog) with a shorter half-life, used in some cancer and transplant contexts, and it is sometimes discussed alongside sirolimus in longevity circles, but it is a different molecule with different pharmacokinetics, not interchangeable dosing.

What monitoring should go alongside any sirolimus protocol?

Blood trough levels, a lipid panel, fasting glucose, and a complete blood count are the standard set, and they should be checked by a prescribing physician who can adjust dose based on results, not guessed at. Sirolimus trough blood levels are used in transplant medicine to keep patients within a defined therapeutic window (commonly cited target ranges for transplant patients run roughly 5 to 15 ng/mL depending on the regimen and organ, per FDA labeling and transplant protocols), and longevity prescribers using off-label weekly dosing typically use trough monitoring for the same reason, to confirm the dose is producing an intended blood concentration without drifting into a range associated with more side effects ^[1]. There's no independently validated "longevity target range" confirmed by outcomes data; prescribers extrapolate from transplant ranges and animal dosing translated to human equivalent doses. A baseline and periodic lipid panel and fasting glucose catch the metabolic effects described above before they become a real problem. A CBC catches unusual drops in white blood cell counts, which would be a signal of more immune suppression than intended. None of this is optional in a well-run protocol. If a source is willing to sell sirolimus without any physician oversight or lab monitoring, that's a red flag, not a convenience.

Where does a legitimate prescription for this actually come from?

From a licensed physician who evaluates you, discusses that this use is off-label, and writes a prescription filled by a real pharmacy, the same process as any other prescription medication, just typically through a longevity-focused telehealth practice rather than a walk-in clinic. Sirolimus Rx works with a provider-review process paired with a named fulfilling pharmacy partner, so the prescription, dosing decision, and lab monitoring sit with a licensed prescriber rather than a self-directed purchase. That structure matters here specifically because dosing needs adjustment based on weight, trough levels, and side effects, none of which a fixed online order can account for. For the practical numbers used inside that process, dose ranges by weight and cycle length between doses are covered in Sirolimus Rx dosage, the Sirolimus Rx dosage calculator, and Sirolimus Rx cycle length. If you want the pharmacokinetic reasoning behind why weekly dosing works at all, Sirolimus Rx half life covers the elimination half-life data that the whole intermittent-dosing idea rests on.

What would I actually tell someone considering this?

Get the mouse data and the human data gap straight in your head before anything else. The mouse data (repeated, multi-lab, dose-responsive, effective even starting late in life) is some of the best animal aging-intervention evidence that exists ^[4][5]. The human lifespan data is zero completed trials. Both of those facts are true at the same time, and neither one should be hidden to make the other point. Don't start this without a physician who will run trough levels and metabolic labs, and don't let anyone sell you a syringe kit for this drug, because that's not how it's used for longevity, and there isn't real safety data behind an injectable version outside the narrow cancer indication for Fyarro ^[2]. If mouth ulcers, cholesterol shifts, or infection risk aren't things you're prepared to monitor for and manage, this isn't a low-commitment supplement, it's a prescription immunosuppressant being used off-label, and it deserves that level of seriousness.

Frequently asked questions

Do you inject sirolimus or take it orally for longevity use?

Orally. Sirolimus is FDA-approved as an oral tablet and oral solution for transplant rejection prevention, and off-label longevity protocols use the same oral formulations, typically dosed weekly rather than daily ^[1]. There is no standard injectable sirolimus product used for longevity; the only injectable-related sirolimus derivative (Fyarro) is approved solely for a rare soft tissue cancer ^[2].

Is there an FDA-approved injectable form of sirolimus?

Yes, but not for longevity. Fyarro is an FDA-approved IV, albumin-bound formulation of nab-sirolimus, approved specifically for malignant perivascular epithelioid cell tumor (PEComa), a rare soft tissue cancer, not for aging or lifespan extension ^[2]. It's administered by IV infusion in a clinical setting, not self-injected at home.

Is sirolimus the same thing as rapamycin?

Yes. Sirolimus is the generic drug name; rapamycin is the original name for the same molecule, isolated from Streptomyces hygroscopicus found in soil on Easter Island ^[1]. The terms are used interchangeably in medical literature, prescribing information, and longevity research.

What is the typical off-label dose for longevity use?

A commonly cited weekly protocol, associated with clinical experience reported by Dr. Alan Green and used across some longevity practices, is roughly 5 to 6 mg once per week, adjusted for body weight and blood trough levels ^[1]. This differs from the roughly 1 to 2 mg daily dosing used in transplant medicine. No dose has been validated in a completed human lifespan trial.

What does the actual human lifespan evidence for sirolimus show?

None yet, because no completed human trial has measured lifespan or all-cause mortality with sirolimus in healthy adults. Human data exist only for surrogate markers like infection rates and vaccine response in older adults using a related TOR inhibitor, RTB101 ^[6][7]. The strong evidence for lifespan extension comes entirely from mouse studies, primarily the NIA Interventions Testing Program ^[4][5].

How much does rapamycin extend lifespan in mice?

The NIA Interventions Testing Program found rapamycin extended median mouse lifespan by roughly 9% to 26%, depending on dose, sex, and age at which treatment started, with benefits seen even when dosing began at 600 days of age (roughly a 60-year-old human equivalent) ^[4]. This is animal data; no equivalent human figure exists.

What are the main risks of sirolimus at longevity doses?

Immunosuppression (with associated infection and malignancy risk noted in the FDA boxed warning), mouth ulcers (a commonly reported side effect), and metabolic changes including elevated LDL cholesterol, triglycerides, and blood glucose ^[1]. These risks are documented from transplant-dose data; whether lower intermittent longevity dosing meaningfully reduces them hasn't been confirmed in long-term human trials.

Can you drink grapefruit juice while taking sirolimus?

No. The FDA label for Rapamune specifically instructs against taking sirolimus with grapefruit juice, because grapefruit inhibits the CYP3A4 enzyme responsible for metabolizing the drug, which can push blood concentrations to unsafe levels ^[1]. Water or orange juice are the specified mixing options for the oral solution.

Why do people mix up sirolimus with injectable peptides?

Because sirolimus is discussed in the same longevity forums and telehealth platforms as injectable peptides like BPC-157 or ipamorelin, and some people assume the administration method carries over. It doesn't: sirolimus is an oral tablet or solution, dispensed like any standard prescription drug, not a reconstituted vial-and-syringe product.

What blood tests should accompany a sirolimus protocol?

A sirolimus trough level, a lipid panel, fasting glucose, and a complete blood count are the standard monitoring set, checked at baseline and periodically by the prescribing physician ^[1]. Trough level targets are extrapolated from transplant medicine ranges, since no independently validated longevity-specific target range exists yet.

Is there a topical version of sirolimus?

Yes, but only for a specific approved indication. Hyftor is an FDA-approved topical sirolimus gel for skin lesions (facial angiofibromas) associated with tuberous sclerosis complex ^[3]. It is not an approved or well-studied option for general skin aging, and it's a different route entirely from oral longevity dosing.

How is sirolimus different from everolimus?

Both are rapalogs (rapamycin analogs) that inhibit mTOR, but everolimus has a shorter half-life and different pharmacokinetics, and is used in distinct cancer and transplant contexts. They are not interchangeable at the same doses, and most off-label longevity protocols and the mouse lifespan data specifically involve sirolimus/rapamycin, not everolimus.

Sources

1. FDA, Hyftor (sirolimus) topical gel approval: Hyftor is an FDA-approved topical sirolimus gel for facial angiofibromas associated with tuberous sclerosis complex
2. Harrison et al., Nature 2009, NIA Interventions Testing Program: Rapamycin extended median lifespan in genetically heterogeneous mice across multiple labs, including when started late in life
3. Bitto et al., eLife 2016, transient rapamycin treatment: Transient rapamycin treatment starting at 20 months of age extended lifespan in mice
4. Mannick et al., Science Translational Medicine 2018: TOR inhibitor RTB101 reduced incidence of respiratory tract infections in elderly volunteers
5. Mannick et al., Science Translational Medicine 2014: Low-dose mTOR inhibitor treatment improved influenza vaccine response in adults over 65